OncLive TV

Robert M. Rifkin, MD, FACP, offers advice to colleagues about belantamab mafodotin as a treatment option for patients with relapsed/refractory multiple myeloma.

Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell therapy and ongoing efforts to expand its application beyond B-cell malignancies.

Jian Zhang, MD, discusses SIM0270, a brain-penetrant oral SERD, in combination with everolimus, in ER-positive, HER2-negative advanced breast cancer.

Carsten Niemann, MD, PhD, discusses long-term follow-up data from the phase 3 GLOW trial evaluating fixed-duration ibrutinib plus venetoclax in CLL.

Jae Park, MD, discusses the FDA approval of obe-cel for adult patients with relapsed or refractory acute lymphoblastic leukemia.

David A. Braun, MD, PhD, discusses the potential use of protein glycosylation as a biomarker of response in renal cell carcinoma.

Bradley McGregor, MD, discusses the rationale for investigating nivolumab plus ipilimumab in advanced, rare genitourinary malignancies.

Francisco J. Hernandez-Ilizaliturri, MD, discusses findings from a study investigating immunologic changes in patients with CLL treated with venetoclax.

Rahul Banerjee, MD, FACP, discusses treatment de-escalation strategies with the use of bispecific antibodies in patients with relapsed multiple myeloma.

Monica H. Vetter, MD, on the implications for inclusion criteria for insurance approvals for pembrolizumab- and dostarlimab-based regimens in endometrial cancer.

Ian Krop, MD, PhD, discusses SHR-A1811, a third-generation antibody-drug conjugate for HER2-positive breast cancer.

Marco Davila, MD, PhD, explains the role of intrinsic tumor drivers in CD19 CAR T-cell therapy resistance in aggressive large B-cell lymphoma.

Yvonne Mowery, MD, PhD, discusses the SU2C-SARC032 trial of pembrolizumab plus radiotherapy followed by surgery in soft tissue sarcoma.

Gustavo Werutsky, MD, PhD, discusses an exploratory analysis that outlined associations between HER2-low breast cancer subtype and clinical outcomes.

Ewa Kalinka, MD, PhD, discusses interim phase 2 data with frontline BMS-986012 plus nivolumab and chemotherapy in extensive-stage small cell lung cancer.

Rohan Garje, MD, discusses the unmet needs for patients with small cell bladder cancer.

Aparna Parikh, MD, discusses the importance of upfront molecular testing in patients with metastatic colorectal cancer.

Tycel Phillips, MD, MPH, discusses the rationale of the phase 1/2 NP30179 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

Muhamed Baljevic, MD, discusses the efficacy and safety of selinexor in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Monzr M. Al Malki, MD, discusses the potential use of TSC-100 and TSC-101 following allogeneic stem cell transplant in patients with AML, ALL or MDS.

Naval G. Daver, MD, discusses the potential role for menin inhibitors in the frontline treatment of patients with acute myeloid leukemia.

Ami Umesh Badami, MD, discusses clinical research that has informed treatment selection in the second-line clear cell renal cell carcinoma setting.

Philip Philip, MD, discusses considerations for selecting first-line treatment for newly diagnosed, low-risk gastrointestinal neuroendocrine tumors.

Katherine L. Nathanson, MD, discusses the identification of reversion mutations in BRCA1/2 in response to therapy among patients with breast cancer.

Pedro Barata, MD, discusses improved clinical outcomes with darolutamide in metastatic hormone-sensitive prostate cancer.

Anthony M. Hunter, MD, discusses the development of, and future roles for JAK, BET, and BCL2/BCL-XL inhibitors in myelofibrosis.

Thomas Westbrook, MD, discusses the non–clear cell renal cell carcinoma research that informs his clinical practice.

John K. Lee, MD, PhD, discusses the EV-302 trial of frontline enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Tae Min Kim, MD, PhD, discusses the efficacy of odronextamab monotherapy in patients with relapsed/refractory marginal zone lymphoma.

Whitney Goldsberry, MD, discusses the potential risk of secondary malignancies in patients with ovarian cancer receiving PARP inhibitors.